ArticleJournal of nanobiotechnology2025
3D printed, biodegradable, and biocompatible intraperitoneal implants loaded with folic acid-targeted/pH-sensitive/doxorubicin-loaded hydroxyapatite nanoparticles for systemic treatment of metastatic breast cancer.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-dimensional porous scaffolds with the capability of controlled drug release have gained increasing interest in chemotherapy due to their sustained release of drugs and ability to reduce systemic toxicity. In this study, we advanced this concept by incorporating drug-loaded nanocarriers into 3D-printed scaffolds, creating trackable constructs for medical imaging such as CT-scan. Doxorubicin-loaded/folic acid-targeted pH-sensitive nanohydroxyapatite (Dox@nHA-FA) were synthesized and incorporated into gelatin/polycaprolactone/hydroxyapatite (Gel/PCL/HA) scaffolds via 3D printing. The Gel/PCL/HA(Dox@HA-FA) scaffolds were extensively characterized for drug release, mechanical strength, microstructure, and degradation profile. In vivo, scaffolds with different compositions were implanted in tumor-bearing Balb/c mice, and their degradation was monitored by CT-scan. The optimized scaffold composition shown medium disintegration tendency within 14 days and superior handling properties. In the orthotopic breast cancer model, Gel/PCL/HA(Dox@HA-FA) scaffolds produced a 71.8% reduction in tumor volume compared with untreated controls (P < 0.01), a 63.0% reduction versus free Dox (P < 0.05), and a 41.5% reduction versus Dox@HA-FA nanoparticles (P < 0.05). In addition, the number of metastatic liver colonies was reduced by ~65% compared with free Dox and by ~48% compared with Dox@HA-FA (P < 0.05). In the diffuse peritoneal metastasis model, Gel/PCL/HA(Dox@HA-FA) scaffolds led to a significant reduction (> 70%, P < 0.01) in peritoneal metastatic nodules, whereas the other groups showed widespread dissemination. Biocompatibility was confirmed by histopathology and blood biochemistry, with no significant alterations in liver or kidney function markers compared with healthy controls (P > 0.05). Importantly, the scaffolds' radio-opaque properties enabled non-invasive CT monitoring of degradation. Together, these results demonstrate that Gel/PCL/HA(Dox@HA-FA) scaffolds provide dual-targeted, sustained drug delivery with significant anti-tumor and anti-metastatic efficacy in vivo, supporting their potential for translation into local chemotherapy of advanced cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.